VERU

VERU

USD

Veru Inc. Common Stock

$2.650+0.070 (2.713%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$2.580

Hoch

$2.650

Tief

$2.580

Volumen

0.18M

Unternehmensfundamentaldaten

Marktkapitalisierung

42.5M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.18M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $2.42Aktuell $2.650Hoch $14.2

KI-Analysebericht

Zuletzt aktualisiert: 10. Nov. 2025
KI-generiertDatenquelle: Yahoo Finance, Bloomberg, SEC

VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges

Market Snapshot

Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns


Recent Performance: Turbulent Descent

Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:

  • Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
  • Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
  • Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.

Technical Signals: Mixed Messages

  • Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
  • Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
  • MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.

Fundamentals: Value Trap or Hidden Potential?

  • Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
  • **High-Risk

Ähnliche Nachrichten

GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Mehr anzeigen
Veru to Present Two Abstracts at ObesityWeek 2025
GlobeNewswire

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Mehr anzeigen
Veru Announces Pricing of $25 Million Public Offering

KI-VorhersageBeta

KI-Empfehlung

Bullisch

Aktualisiert am: 10. Nov. 2025, 14:42

BärischNeutralBullisch

58.4% Konfidenz

Risiko & Handel

Risikostufe3/5
Mittleres Risiko
Geeignet für
Wert
Handelsleitfaden

Einstiegspunkt

$2.52

Gewinnmitnahme

$2.61

Stop-Loss

$2.30

Schlüsselfaktoren

PDI 15.4 liegt über MDI 14.1 mit ADX 19.0, was auf einen bullischen Trend hindeutet
Handelsvolumen ist 1.9x Durchschnitt (3,174), was auf erhöhte Marktbeteiligung hindeutet
MACD 0.0119 liegt unter der Signallinie 0.0162, was auf einen bärischen Crossover hindeutet

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.